Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Imatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.